Beam Therapeutics Sell-Off: Updated Phase 1/2 Data on BEAM-302 for AATD
Beam shares fell after updated BEAM-302 data showed durable AAT correction. Incremental results sparked classic biotech profit-taking.
/ 8 items
#BEAM↓
Prime Medicine Wins Arbitration Dispute with Beam Therapeutics, Clears Path for PM647
Prime Medicine secures positive arbitration ruling against Beam Therapeutics: no damages owed for PM647 in AATD. IND/CTA filing planned for Q3 2026, first clinical data in 2027.
William Blair Bullish on Beam Therapeutics Following Strategic Update
William Blair maintains Outperform rating on Beam Therapeutics after company announces FDA alignment for BEAM-302 and planned risto-cel application, citing clear regulatory pathway ahead.
Evercore ISI Begins Coverage of Beam Therapeutics With Bullish Outlook
Evercore ISI initiates coverage of Beam Therapeutics (BEAM) with an Outperform rating and $35 price target, citing promising early data for BEAM-302 in treating AATD and highlighting key data expected in Q1 2026.
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.
Intellia Pauses Gene Therapy Trials After Patient Develops Severe Liver Injury
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.